Gut podcast
Summary: From June 2023, all our podcasts will move to https://gutbmj.podbean.com. You can continue with your subscription on your favourite podcast App. Gut is a leading international journal in gastroenterology and hepatology. It has an established reputation for publishing first class clinical research of the alimentary tract, the liver, biliary tree and pancreas. Gut delivers up-to-date, authoritative, clinically oriented coverage of all areas in gastroenterology. Regular features include articles by leading authorities, reports on the latest treatments for diseases, reviews and commentaries. Subscribers to Gut also receive Frontline Gastroenterology (FG). The Gut Podcast discusses highlights from its issues monthly. Please subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
- Visit Website
- RSS
- Artist: BMJ Group
- Copyright: 643134
Podcasts:
Mairi McLean talks to Krisztina Gecse about the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Read the related article: http://gut.bmj.com/content/63/9/1381.full
Mairi McLean talks to Krisztina Gecse about the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Read the related article: http://gut.bmj.com/content/63/9/1381.full
The identification of a distinct syndrome, designated eosinophilic oesophagitis (EoE), with its own clinical and histopathological characteristics, was first described in the early 1990s. Meanwhile intense research has uncovered many molecular, immunological and clinical aspects of this chronic-inflammatory disorder. In this podcast, Mairi McLean talks to Professor Alex Straumann, Swiss EoE Clinic and EoE Research Network, about the basic and clinical insights of EoE gathered during the last few years. Read Professor Straumann's update on the topic: http://goo.gl/0B6h14
The identification of a distinct syndrome, designated eosinophilic oesophagitis (EoE), with its own clinical and histopathological characteristics, was first described in the early 1990s. Meanwhile intense research has uncovered many molecular, immunological and clinical aspects of this chronic-inflammatory disorder. In this podcast, Mairi McLean talks to Professor Alex Straumann, Swiss EoE Clinic and EoE Research Network, about the basic and clinical insights of EoE gathered during the last few years. Read Professor Straumann's update on the topic: http://goo.gl/0B6h14
Inflammatory bowel disease is driven by a seemingly aberrant immune response to the gut microbiota with disease development dictated by genetics and environmental factors. A model exemplifying this notion is work by Andrew Gewirtz, Center for Inflammation, Immunity, & Infection, Georgia State University, and colleagues, demonstrating that colonisation of adherent-invasive Escherichia coli (AIEC) during microbiota acquisition drove chronic colitis in mice lacking the flagellin receptor TLR5 (T5KO). They have now published a paper in Gut hypothesising that AIEC instigates chronic inflammation by increasing microbial lipopolysaccharide and flagellin levels, and investigating how AIEC colonisation might instigate colitis in T5KO mice. Mairi McLean talks to Dr Gerwitz about their findings. Read the full paper (for free): http://gut.bmj.com/content/63/7/1069.full
Inflammatory bowel disease is driven by a seemingly aberrant immune response to the gut microbiota with disease development dictated by genetics and environmental factors. A model exemplifying this notion is work by Andrew Gewirtz, Center for Inflammation, Immunity, & Infection, Georgia State University, and colleagues, demonstrating that colonisation of adherent-invasive Escherichia coli (AIEC) during microbiota acquisition drove chronic colitis in mice lacking the flagellin receptor TLR5 (T5KO). They have now published a paper in Gut hypothesising that AIEC instigates chronic inflammation by increasing microbial lipopolysaccharide and flagellin levels, and investigating how AIEC colonisation might instigate colitis in T5KO mice. Mairi McLean talks to Dr Gerwitz about their findings. Read the full paper (for free): http://gut.bmj.com/content/63/7/1069.full
Despite the success of hepatitis B virus vaccination in preventing new infection in endemic areas, chronic hepatitis B still poses a heavy burden globally. There are approximately 350 million carriers in the world, with an estimated 60 000 persons dying annually of hepatitis B-related cirrhosis and hepatocellular carcinoma. In a study recent published in Gut, Professor Man-Fung Yuen, Department of Medicine, The University of Hong Kong, and colleagues, report the results of viral suppression and safety of two doses of besifovir, with entecavir as a comparator in treatment-naive subjects for 48 weeks. He talks to Mairi McLean about the findings. Read the full paper: Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B http://gut.bmj.com/content/63/6/996.full
Despite the success of hepatitis B virus vaccination in preventing new infection in endemic areas, chronic hepatitis B still poses a heavy burden globally. There are approximately 350 million carriers in the world, with an estimated 60 000 persons dying annually of hepatitis B-related cirrhosis and hepatocellular carcinoma. In a study recent published in Gut, Professor Man-Fung Yuen, Department of Medicine, The University of Hong Kong, and colleagues, report the results of viral suppression and safety of two doses of besifovir, with entecavir as a comparator in treatment-naive subjects for 48 weeks. He talks to Mairi McLean about the findings. Read the full paper: Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B http://gut.bmj.com/content/63/6/996.full
Mairi McLean talks to Robin Spiller, NIHR Nottingham Digestive Diseases Biomedical Research Unit, and David Tooth, School of Biomedical Sciences, University of Nottingham, about their paper: Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit.Read the full article: http://goo.gl/0OIP34
Mairi McLean talks to Robin Spiller, NIHR Nottingham Digestive Diseases Biomedical Research Unit, and David Tooth, School of Biomedical Sciences, University of Nottingham, about their paper: Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit.Read the full article: http://goo.gl/0OIP34
Mairi McLean talks to Andres Acosta and Barham K Abu Dayyeh, both Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, about their review on the management of obesity.Read the full paper: http://goo.gl/V37xaq
Mairi McLean talks to Andres Acosta and Barham K Abu Dayyeh, both Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, about their review on the management of obesity.Read the full paper: http://goo.gl/V37xaq
Necrotising enterocolitis (NEC) remains one of the primary causes of morbidity and mortality in neonates and alternative strategies are needed. Stem cells have become a therapeutic option for other intestinal diseases, which share some features with NEC. Along with colleagues, Simon Eaton and Paolo De Coppi, both from University College London Institute of Child Health, have tested the hypothesis that amniotic fluid stem (AFS) cells exerted a beneficial effect in a neonatal rat model of NEC.Mairi McLean discusses their findings with them.Read the full paper:Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism http://goo.gl/EFUuN0
Necrotising enterocolitis (NEC) remains one of the primary causes of morbidity and mortality in neonates and alternative strategies are needed. Stem cells have become a therapeutic option for other intestinal diseases, which share some features with NEC. Along with colleagues, Simon Eaton and Paolo De Coppi, both from University College London Institute of Child Health, have tested the hypothesis that amniotic fluid stem (AFS) cells exerted a beneficial effect in a neonatal rat model of NEC.Mairi McLean discusses their findings with them.Read the full paper:Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism http://goo.gl/EFUuN0
Gut's education editor Mairi McLean discusses highlights from the guidelines on the diagnosis and management of Barrett's oesophagus with authors Rebecca Fitzgerald and Massimiliano di Pietro, both from the MRC Cancer Unit, University of Cambridge.Read the full paper here: http://bit.ly/1kkPkVW
